期刊文献+

EGFR磷酸化水平与乳腺癌术后生存期的关系评价 被引量:1

Relationship between EGFR phosphorylation and the postoperative survival of breast cancer patients
在线阅读 下载PDF
导出
摘要 目的探讨表皮生长因子受体(EGFR)的磷酸化水平与乳腺癌细胞生物学行为及患者术后生存期的关系。方法采用双染免疫组化检测60例乳腺癌组织中EGFR和磷酸化EGFR(p-EGFR)的表达,分析两者与乳腺癌生物学行为、术后无瘤生存期及总生存期的关系。结果60例乳腺癌标本EGFR阳性率81.67%(49/60),p-EGFR阳性率60.0%(36/60)。EGFR阳性率与分化程度密切相关,而p-EGFR则与分化程度、淋巴结转移、临床分期密切相关,在低分化、有淋巴结转移、进展晚期的乳腺癌中表达明显升高。Kaplan—Meier生存曲线及log—rank分析发现,EGFR与乳腺癌患者术后总生存期(Os)和无瘤生存期(DFS)无关,而p-EGFR表达水平与乳腺癌患者无瘤生存期(DFS)显著相关,p-EGFR高表达组患者DFS比阴性组乳腺癌患者缩短。结论乳腺癌组织EGFR蛋白磷酸化激活是影响乳腺癌患者术后生存期的重要因素。EGFR被激活后的磷酸化水平能更好地反映乳腺癌的生物学行为,并对患者的预后判断有一定帮助。 Objective To explore the relationship between phosphorylated levels of epidermal growth factor receptor (EGFR) and the biological behaviors of breast cancer and the postoperative survival of cancer patients. Methods The levels of total EGFR and phosphorylated EGFR (p -EGFR) were detected in sixty breast cancer tissues by double immunohistochemical staining. Then, their relationship with the biological behaviors of breast cancer, the postoperative disease - free survival (DFS) and overall survival in cancer patients were analyzed. Results These cancer specimens showed a positive rate of 81.67% (49/60) for EGFR and 60.0% (36/60) for p - EGFR. The positive rate of EGFR was related with the differentiation of cancer cells. In contrast, the positive rate of p - EGFR was associated with the differentiation of cancer cells, lymph node metastasis and clinical phases. The amount of p - EGFR was remarkably increased in poorly differentiated, advanced cancer with lymph node metastasis. According to the Kaplan - Meier curve and log - rank analysis, the level of EGFR was not related with DFS and overall survival of cancer patients, while the quantity of p - EGFR was closely associated with DFS of cancer patients. The patients presenting a high level of p - EGFR showed a shorter DFS than those with negative p - EGFR expression. Conclusion The phosphorylation of EGFR is an important factor associated with postoperative survival in breast cancer patients. The level of phosphorylated EGFR can reflect the biological behaviors of breast cancer, which is helpful for assessing the prognosis of patients.
出处 《徐州医学院学报》 CAS 2015年第9期571-576,共6页 Acta Academiae Medicinae Xuzhou
关键词 乳腺癌 信号通路 表皮生长因子受体 磷酸化 预后 breast cancer signaling pathway epidermal growth factor receptor phosphorylation prognosis
作者简介 通信作者,E—mail:xdhuang3970808@sina.com
  • 相关文献

参考文献14

  • 1Hemandez -Hernandez OT, Camacho -Arroyo I. Regulation ofgene expression by progesterone in cancer cells: effects on cyclin D1, EGFR and VEGF [J]. Mini Rev Med Chem, 2013, 13(5) : 635 - 642.
  • 2Mitrasinovic PM. Some implications of receptor kinase signaling pathway for development of multitargeted kinase inhibitors [ J ]. Curr Radiopharm, 2013, 6( 1 ) :48 -55.
  • 3Efferth T. Signal transduction pathways of the epidermal growth factor receptor in colorectal cancer and their inhibition by small molecules [J]. Curr Med Chem, 2012, 19(33) :5735 -5744.
  • 4Porcelli L, Quatrale AE, Mantuano P, et al. Synergistic antipro- liferative and antiangiogenic effects of EGFR and roTOR inhibitors [J]. Gun-Pharm Des, 2013,19(5) :918 -926.
  • 5Berg M, Soreide K. EGFR and downstream genetic alterations in KRAS/BRAF and PBK/AKT pathways in colorectalcancer: impli- cations for targeted therapy [J]. Discov Med, 2012, 14(76) :207 -214.
  • 6Brand TM, Iida M, Luthar N, et al. Nuclear EGFR as a molecu- lar target in cancer [ J ]. Radiother Oncol, 2013, 108 (3) :370 - 377.
  • 7谢小红,顾锡冬,赵虹,胡袁媛.973例乳腺癌患病相关危险因素分析[J].中华全科医学,2014,12(6):960-962. 被引量:23
  • 8Nakata A, Gotoh N. Recent understanding of the molecular mech- anisms for the efficacy and resistance of EGF receptor - specific tyrosine kinase inhibitors in non - small cell lung cancer [ J]. Ex- pert Opin Ther Targets, 2012,16(8) :771 -781.
  • 9Pozo N, Zahonero C, Fernndez P, et al. Inhibition of DYRKIA destabilizes EGFR and reduces EGFR - dependent glioblastoma growth [J]. J Clin Invest, 2013, 123(6) :2475 -2487.
  • 10Khler J, Schuler M. Afatinib, erlotinib and gefitinib in the first - line therapy of EGFR mutation - positive lung adenocareino- iew [J]. Onkologie, 2013, 36(9) :510-518.

二级参考文献19

  • 1Nelson HD, Zakher B, Cantor A, et al. Risk factors for breast cancer for women aged 40 to 49 years:a systematic review and meta-analysis [ J ]. Ann Intern Med,2012,156(9) :635-648.
  • 2Lech R, Przemystaw O. Epidemiological models for breast cancer risk estimation[ J]. Ginekol Pol,2011,82(6) :451-454.
  • 3Wen Y Chay,Whee S Ong,Puay H Tan,et al. Validation of the Gail model for predicting individual breast cancer risk in a prospective na- tionwide study of 28,104 Singapore women[J]. Breast Cancer Res, 2012,14(1) :R19.
  • 4Vetto JT, Luoh SW, Naik A. Breast cancer in premenopausal women [ J]. Curr Probl Surg,2009,46 ( 12 ) :944-1004.
  • 5Tao W, Wang C, Han R, et al. HER2 codon 655 poly-morphism and breast cancer risk: a meta-analysis [ J ]. Breast Cancer Res Treat, 2009,114(2) :371-376.
  • 6Swaminathan R, Seivakumaran R, Vinodha J, et al. Educatlonanal cancer incidence in a rural population in south India[J]. Cancer Ep- idemio1,2009,33 (2) :89-93.
  • 7Vendhan Gajalakshmi, Aleyamma Mathew, Paul Brennan, et al. Breastfeeding and breast cancer risk in India: A multicenter case- control study[ J ]. International Journal of Cancer, 2009,125 ( 3 ) : 662-665.
  • 8陈小艳,宋文静.6207例乳腺肿瘤临床病理资料分析[J].肿瘤防治研究,2009,36(9):797-800. 被引量:11
  • 9夏建红,王颀,张安秦,李文萍,许娟,陈中扬,杨剑敏,翁秀琼.广东地区妇女乳腺癌预测模型的研究[J].中华乳腺病杂志(电子版),2009,3(5):22-26. 被引量:11
  • 10姚舒洋,徐兵河.年轻女性乳腺癌临床病理特点及治疗策略[J].临床药物治疗杂志,2010,8(6):35-40. 被引量:6

共引文献22

同被引文献4

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部